Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02277574 · ClinicalTrials.gov registry record · Phase 1
Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02277574 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 29 participants.
The verdict
NCT02277574, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1b, randomized, multi-dose, placebo-controlled, dose-escalation, multi-center study of AMP-110 in adult subjects with rheumatoid arthritis.
Interventions
- OTHER Placebo
- BIOLOGICAL AMP-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02277574
The ClinicalTrials.gov registry entry for NCT02277574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02277574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02277574 about?
NCT02277574 is a clinical study titled "Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis". This is a Phase 1b, randomized, multi-dose, placebo-controlled, dose-escalation, multi-center study of AMP-110 in adult subjects with rheumatoid arthritis.
What is the current status of trial NCT02277574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02277574?
The interventions under investigation include: Placebo (OTHER), AMP-110 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02277574?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.